Where Innovation Meets Implementation.
The Process behind the Progress.
Connecting Europe’s bioprocess leaders to scale biologics, mAbs, conjugates, ATMPs and complex molecules into commercial therapies.
5 Tracks. 4 Workshops. Countless Real-World Solutions.
Advance Technologies. Accelerate Production. Transform Bioprocessing.
Ready to progress your process? The BioProcess International (BPI) Europe 2027 agenda is where innovation meets implementation. Get the blueprint to master complex modalities, scale your pipeline, and define the future of medicine.
Cell Line Development & Engineering
- Apply active machine learning (ML) algorithms for high-throughput clone screening and phenotypic profiling.
- Predict and ensure long-term genetic, epigenetic, and phenotypic stability from early clone selection to commercial scale-up.
- Link clone selection beyond titre to critical quality attributes (CQAs), host cell protein (HCP) burdens, and commercial manufacturability.
- Engineer stable, high-yielding host lines for novel multispecific antibodies, ADCs, and complex expression platforms.
Cell Culture & Upstream Processing
- Optimise media formulations and dynamic feeds to simplify downstream purification steps and reduce upstream COGs.
- Master upstream process intensification, perfusion setups, and N-1 high-density cell culture systems.
- Deploy real-time PAT, FT-IR optical sensors, and digital twins for automated bioreactor feedback and process control.
- Leverage cross-industry precision fermentation innovations to solve fluid dynamics and mass transfer bottlenecks at scale.
Downstream Processing
- Benchmark high-throughput membrane adsorbers vs. resin columns using automated pH and conductivity gradient screening.
- Transition polishing operations to continuous multi-column chromatography (MCC) setups to maximize yield step efficiency.
- Integrate real-time downstream PAT spectroscopy for automated fraction collection and inline purity monitoring.
- Advance facility sustainability with automated inline buffer formulation, solvent reclamation, and reduced tank footprints.
Advanced & Complex Modalities
- Resolve host cell DNA clearance challenges and align with evolving regulatory specifications and standards.
- Optimise full vs. empty AAV capsid separation using precise anion-exchange (AEX) chromatography gradients.
- Scale allogeneic cell therapies and extracellular vesicles (EVs) using closed, automated bioreactor platforms.
- Control upstream variables to ensure consistent antibody-drug conjugate (ADC) structure, DAR ratios, and linker stability.
*NEW for 2027* CMC Strategy & Manufacturing Performance
- Structure phase-appropriate CMC packages and navigate accelerated IND/BLA regulatory approval pathways for complex biologics.
- De-risk global tech transfer, multi-site supply chain resilience, and strategic CDMO relationship management.
- Modernize biomanufacturing facilities and streamline post-approval change controls using ICH Q12 regulatory tools.
- Validate predictive AI models and digital twins in GMP environments under GAMP 5 guidelines and the EU AI Act.
Upskill with Hands-On Pre-Conference Workshops
Deepen your technical expertise with interactive full-day pre-conference workshops led by industry leaders.
- Advanced Process Intensification & Continuous Biomanufacturing
- Engineering Robustness in Modern DSP
- AI & ML Applicability in Bioprocessing
- Managing Change in Biopharmaceutical CMC Development
BPI Europe Returns to Hamburg – Where Biomanufacturing Excellence Meets Global Innovation
Join us as BPI Europe returns to Hamburg, a premier central gateway for European biomanufacturing. Anchored by the Life Science Nord cluster and renowned research hubs like DESY and UKE, the region bridges world-class academic research with commercial-scale manufacturing excellence. With seamless international transport links and a dense network of biopharma leaders, Hamburg provides the ideal backdrop to connect with peers, de-risk global supply chains, and advance bioprocessing innovation.
Prepare for the Future of Biomanufacturing at BPI Europe.
Bioprocessing in 2027 is defined by patent cliffs, fierce global market competition, evolving regulatory standards, and rapid modality expansion. To secure commercial viability, biopharma leaders are rethinking raw material strategies, digital validation, and facility design to drive down COGs and de-risk global tech transfer. Three strategic imperatives now shape biomanufacturing decisions across Europe: COGs & Commercial Viability, Regulatory Strategy & Speed, and Digital & Intensified Biomanufacturing.
COGs & Commercial Viability
With patent cliffs looming and market competition intensifying, lowering total cost of goods (COGs) is essential to protecting long-term margins.
Go beyond theory to defend your margins and streamline operations:
- Optimize media formulations and raw material strategies to simplify downstream purification and cut upstream bioprocessing COGs.
- Establish strategic CDMO partnerships and multi-site tech transfer frameworks to secure global supply chain resilience.
- Reduce facility footprint and environmental impact through inline buffer formulation, solvent reclamation, and single-use systems.
Master commercial viability at BPI Europe:
Reduce cost per batch, eliminate tech transfer roadblocks, and build resilient, sustainable biomanufacturing networks.
Regulatory Strategy & Speed
True speed requires navigating complex regulatory landscapes to accelerate IND/BLA filings without triggering expensive re-validation backlogs.
Go beyond theory to de-risk filings and accelerate time-to-market:
- Structure flexible, phase-appropriate CMC packages tailored for accelerated clinical entry and breakthrough designations.
- Align with evolving FDA and EMA specifications for residual host cell DNA and impurity clearance in viral vectors.
- Modernize legacy commercial facilities and streamline post-approval changes using ICH Q12 regulatory tools.
Unlock regulatory speed at BPI Europe:
Translate technical risk evaluations into actionable regulatory strategies that satisfy global licensing authorities.
Digital & Intensified Biomanufacturing
Unlocking the next generation of bioprocessing requires validating predictive AI and continuous workflows within strict GMP environments.
Go beyond theory to deploy predictive, automated biomanufacturing:
- Deploy active machine learning (ML) algorithms early to predict clone stability, HCP burdens, and CQAs from Day 0.
- Validate predictive algorithms and digital twins under GAMP 5 frameworks and the newly active EU AI Act.
- Implement intensified perfusion and continuous multi-column chromatography (MCC) supported by inline PAT sensors.
Future-proof your biomanufacturing toolbox at BPI Europe:
Move from retrospective offline testing to proactive, automated process oversight across multi-product facilities.
Meet the People Rewriting the Bioprocessing Playbook
Want to know where the bioprocessing industry is headed? Be in the room where it's discussed.
While we are carefully crafting the 2027 Agenda, explore our 2026 line-up. A masterclass in bioprocessing, featuring global pharma leaders and innovative biotechs sharing their toughest lessons. Get exclusive insights you won’t find in journals...straight from the experts.
Who will you meet at BioProcess International Europe?
BioProcess International Europe at a Glance
+
Participants from across all phases of bioprocessing
+
Meetings arranged on the ConnectMe app in 2025
+
Hours of Scientific Content
+
Experts Sharing Cutting-Edge Research
Hours of Dedicated Networking Time
Conference Tracks across the Bioprocessing Spectrum
Feel the Pulse of Europe's Bioprocessing Community
From the exhibit floor to the conference halls, BioProcess International Europe 2026 in Vienna was alive with collaboration, discovery, and the kind of momentum that only happens when the best in the industry gather under one roof.
Witness the moments that matter: scientists exchanging game-changing ideas, suppliers showcasing cutting-edge solutions, and an entire community united by one mission - advancing biologics, mAbs, and novel modalities that will transform patient lives.
Engage Qualified Bioprocessing Decision-Makers!
Whether you're increasing your company profile, launching a new product, or focusing on new business development opportunities, collaborate with us to identify custom solutions to help you reach your goals.
Contact us directly at Partners@informaconnectls.com
Get the Latest Event Updates
FAQs
When and where is BioProcess International Europe 2027?
BioProcess International Europe (BPI Europe) will take place on April 27-29, 2027, at the Congress Center Hamburg, Hamburg, Germany.
What is BioProcess International Europe (BPI Europe)?
BPI Europe is Europe's premier bioprocessing conference and exhibition that brings together scientists, innovators, and industry leaders to advance biologics manufacturing. The event focuses on cutting-edge science, strategies, & digital tools to accelerate your journey from molecule to market for mAbs, Biologics, & ATMPs.
Who organizes BioProcess International Europe?
BPI Europe is organized by Informa Connect, a division of Informa PLC. Find out more about Informa’s Life Science events here.
What are the main focus areas for BioProcess International Europe?
BioProcess International (BPI) Europe 2026 focused on several key areas, across 5 tracks and 4 pre-conference workshops, including:
Cell Line Development: Engineering high-producing cell lines for complex biologics with AI and CRISPR.
Upstream Processing: Intensifying upstream processes and de-risking scale-up with digital tools.
Downstream Processing: Purifying novel molecules with continuous processes and next-gen membrane tech.
ATMP Manufacturing: Lowering COGs and reaching patients through automation and advanced analytics.
Digital Biomanufacturing: Building the smart factory by integrating data and implementing AI-driven digital twins.
Who spoke at BioProcess International Europe 2026?
View our expert speakers including industry leaders, scientists, and trailblazers on our Speaker Page here.
Are there sponsorship opportunities available?
Custom sponsorship opportunities are available to help you reach your business objectives, whether you're looking to generate quality leads, showcase thought leaders, or reinforce your brand. For more information, contact partners@informaconnectls.com.
View the Sponsor Prospectus, Floorplan, and more on our Sponsors & Exhibitors page.
What is the difference between BioProcess International events and the BioProcess International publication?
BioProcess International operates as both an event series and a media publication, each serving distinct purposes within the biopharmaceutical industry.
BioProcess International events are industry-leading conferences and exhibitions that bring together bioprocessing professionals for in-person knowledge exchange and networking. Our events include:
- BioProcess International Europe (BPI Europe): This event, held in Vienna, Austria, for 2026, focuses on bioprocessing mastery for European market.
- BioProcess International (BPI) : Held in Boston, US and part of Biotech Week Boston, focuses on established biomanufacturing, regulatory deep-dives and digitalization.
- BioProcess International US West (BPI West): Held in San Diego, California, US, emphasizes emerging technologies and West Coast innovation.
- BioProcess International APAC (BPI APAC) : Held in Marina Bay, Singapore, features advances in biologics production for the Asian market.
- BioProcess International India (BPI India): Held in Hyderabad, India, one of the world's fastest-growing biomanufacturing markets, this event focuses on India's dynamic bioprocessing ecosystem.
BioProcess International Publication
BioProcess International is a monthly, controlled-circulation magazine, providing the latest, peer-reviewed information on the development, scale-up, and manufacture of biotherapeutics and biodiagnostics, reaching 35,000+ print subscribers and 50,000+ digital readers globally.
Both the events and publication are part of Informa Connect, a division of Informa PLC.